
Cathay Industrial Biotech
Chinese biotech company producing bio-based materials like long-chain dibasic acids and biopolyamides for sustainable plastics and textiles.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | CNY5.6b Valuation: CNY8.2b 5.5x EV/Revenue 12.6x EV/EBITDA | IPO | |
Total Funding | 000k |






CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | (22 %) | 47 % | 11 % | (13 %) | 40 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 35 % | 43 % | 43 % | 42 % | 37 % | 33 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 25 % | 31 % | 28 % | 23 % | 17 % | 17 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 5 % | 6 % | 6 % | 8 % | 9 % | 8 % |
Source: Company filings or news article
Related Content
Cathay Industrial Biotech operates as a publicly-traded company on the Shanghai Stock Exchange's STAR market, specializing in the research, development, production, and sale of bio-based materials through synthetic biology and bio-manufacturing. The company was founded in 2000 by Dr. Xiucai Liu, who serves as the Chairman and CEO. Dr. Liu's background includes a Ph.D. in Biochemistry from the University of Wisconsin-Milwaukee and postdoctoral positions at Yale and Columbia, providing a strong scientific foundation for the company's focus on industrial biotechnology. A key milestone was the company's IPO on the STAR market in August 2020.
The core of Cathay's business is the production of alternatives to petrochemical-based products, utilizing renewable resources like corn and other crop stalks. Revenue is generated through direct sales of its bio-based products and through strategic partnerships for technology and product development. The company's business model is vertically integrated, spanning from monomer production to polymer synthesis, serving a global client base that includes prominent companies like DuPont, Evonik, and Novo Nordisk. Cathay's primary offerings include a series of long-chain dicarboxylic acids (LCDAs), bio-based pentamethylene diamine (PDA), and bio-based polyamides. The company is a world-leading supplier of bio-manufactured LCDAs, which are used in applications such as nylons, resins, adhesives, and fragrances.
Cathay's main product lines are its bio-based monomers and its subsequent polyamide brands, TERRYL® for textiles and ECOPENT® for engineering applications. The bio-based polyamides (PA5X series) are created from the company's own bio-manufactured PDA and various diacids. These materials offer distinct properties such as inherent flame retardance, high toughness, and low moisture absorption, which stem from their odd-numbered carbon molecular structure. This positions them as sustainable alternatives in markets like automotive, electronics, textiles, and consumer goods, aiming to reduce carbon emissions compared to traditional petroleum-based nylons.
Keywords: synthetic biology, bio-based materials, industrial biotechnology, polyamides, long-chain dicarboxylic acids, pentamethylene diamine, bio-manufacturing, renewable feedstock, chemical alternatives, biomaterials, sustainable chemicals, bioplastics, fermentation process, bio-based polymers, green chemistry, bio-composites, engineering plastics, specialty chemicals, textile materials, automotive materials